New melanin nanomedicines target chronic inflammation

Researchers used an enzyme to guide melanin nanomedicines to inflamed tissues.

Scientists developed melanin nanomedicines to treat chronic inflammation. This strategy uses myeloperoxidase to target specific tissues.

Myeloperoxidase (MPO) is a pathological marker that is elevated in inflamed tissues. Melanin nanomedicines (MNMs) accumulate in these areas through MPO.

In a rat model of hepatopulmonary syndrome (HPS), MNM treatment improved survival rates. This was better than N-acetylcysteine (NAC) and the Tumor Necrosis Factor-alpha (TNF-alpha) monoclonal antibody Infliximab.

The strategy also showed therapeutic efficacy in a mouse model of chronic inflammatory bowel disease (IBD). The MNM platform can load additional therapeutic agents for synergistic effects.

This MPO-mediated strategy may serve as a blueprint for next-generation precision anti-inflammatory therapies.

Key facts

  • Melanin nanomedicines (MNMs) use myeloperoxidase (MPO) for precise targeting to inflammatory tissues.
  • MNM treatment improved survival in a hepatopulmonary syndrome (HPS) rat model compared to N-acetylcysteine (NAC) and Infliximab.
  • The platform showed efficacy in a mouse model of chronic inflammatory bowel disease (IBD).

All sections

Edition